PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11108836-2 2000 Treatment of bone marrow cells with SB203580 but not PD98059 inhibited TNF-induced osteoclast differentiation. SB 203580 36-44 tumor necrosis factor Mus musculus 71-74 10600756-5 1999 The p38 mitogen-activated protein kinase (p38 MAPK) inhibitor SB-203580 also reduced the NO(-2) production evoked by LPS, TNF-alpha, or GM-CSF, but it was not as effective as tyrphostin B42. SB 203580 62-71 tumor necrosis factor Mus musculus 122-131 11018764-8 2000 It was shown by using specific inhibitors of lipid and protein kinases (LY294002, rapamycin, PD98059, SB203580) that both phosphoinositide 3-kinase and MAP kinase pathways contribute to the anti-apoptotic action of IGF-I on serum-starved cells, while phosphoinositide 3-kinase but not MAP kinase activity is required for the paradoxical pro-apoptotic action of IGF-I in the presence of TNF-alpha. SB 203580 102-110 tumor necrosis factor Mus musculus 386-395 9620170-3 1998 To independently investigate the role of Hsp25 phosphorylation, we blocked TNFalpha-induced phosphorylation of wt-Hsp25 using SB203580, a specific inhibitor of the P38 MAP kinase. SB 203580 126-134 tumor necrosis factor Mus musculus 75-83 10329406-3 1999 SB 203580 as the specific inhibitor for p38 MAP kinase activity inhibited TNF-alpha-induced IL-6 production by the parental L cells, indicating that TNF-alpha-activated p38 MAP kinase regulates IL-6 production by the cell lines used in this study. SB 203580 0-9 tumor necrosis factor Mus musculus 74-83 10329406-3 1999 SB 203580 as the specific inhibitor for p38 MAP kinase activity inhibited TNF-alpha-induced IL-6 production by the parental L cells, indicating that TNF-alpha-activated p38 MAP kinase regulates IL-6 production by the cell lines used in this study. SB 203580 0-9 tumor necrosis factor Mus musculus 149-158 8814313-10 1996 The phosphodiesterase type 4 inhibitor, R-rolipram was found to inhibit both human and mouse TNF production while SB CSAID, novel kinase inhibitor SB 203580 inhibited human IL-1 and TNF as well as mouse TNF. SB 203580 147-156 tumor necrosis factor Mus musculus 182-185 9570551-7 1998 The specific p38 inhibitor SB203580 abrogated the mycoplasma-induced IL-6, IL-1beta, and TNF-alpha synthesis. SB 203580 27-35 tumor necrosis factor Mus musculus 89-98 30038619-0 2018 The p38 MAPK Inhibitor SB203580 Abrogates Tumor Necrosis Factor-Induced Proliferative Expansion of Mouse CD4+Foxp3+ Regulatory T Cells. SB 203580 23-31 tumor necrosis factor Mus musculus 42-63 32626961-5 2020 SB203580 inhibited LPS-induced lung injury and proinflammatory cytokine expression, including tumor necrosis factor-alpha and interleukin-1beta. SB 203580 0-8 tumor necrosis factor Mus musculus 94-121 33221976-9 2021 CIA mice treated with LXA4 and SB203580 had lower levels of TNF-alpha, IL-6, IL-1beta, and IFN-gamma, accompanying decreased MDA as well as increased SOD, CAT,and GPx. SB 203580 31-39 tumor necrosis factor Mus musculus 60-69 32953743-11 2020 Elisa"s analysis showed that cell apoptosis increased after TNF-alpha treatment alone, and cell apoptosis was reduced to the normal levels when combined with antimicrobial peptide, and cell apoptosis induced by TNF-alpha was partially abolished when combined with SB203580. SB 203580 264-272 tumor necrosis factor Mus musculus 60-69 32953743-11 2020 Elisa"s analysis showed that cell apoptosis increased after TNF-alpha treatment alone, and cell apoptosis was reduced to the normal levels when combined with antimicrobial peptide, and cell apoptosis induced by TNF-alpha was partially abolished when combined with SB203580. SB 203580 264-272 tumor necrosis factor Mus musculus 211-220 32045770-6 2020 SB203580 and PDTC reduced total cells and neutrophils in BALF in LPS-induced mice, accompanying with decreased levels of TNF-alpha, IL-6, MPO, LPO and MDA and the expressions of beclin-1, Atg5 and LC3II, but with the up-regulated activities of SOD and GSH-Px, as well as p62 protein expression. SB 203580 0-8 tumor necrosis factor Mus musculus 121-130 30038619-5 2018 The results show that treatment with specific p38 MAPK inhibitor SB203580, rather than NF-kappaB inhibitors (Sulfasalazine and Bay 11-7082), abrogated TNF-induced expansion of Tregs in vitro. SB 203580 65-73 tumor necrosis factor Mus musculus 151-154 30038619-6 2018 Furthermore, upregulation of TNFR2 and Foxp3 expression in Tregs by TNF was also markedly inhibited by SB203580. SB 203580 103-111 tumor necrosis factor Mus musculus 29-32 29412160-6 2018 After adding p38 inhibitor, SB203580 to culture, the production of IL-1beta, IL-6, IL-10, TNF-alpha was significantly reduced as compared to visfatin only (P < 0.01). SB 203580 28-36 tumor necrosis factor Mus musculus 90-99 28155010-9 2017 Finally, pretreatment with p38 inhibitor, SB203580, attenuated the pIONL-induced mechanical allodynia and decreased the mRNA expression of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) in the TG. SB 203580 42-50 tumor necrosis factor Mus musculus 176-203 28155010-9 2017 Finally, pretreatment with p38 inhibitor, SB203580, attenuated the pIONL-induced mechanical allodynia and decreased the mRNA expression of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) in the TG. SB 203580 42-50 tumor necrosis factor Mus musculus 205-214 27920472-7 2016 RESULTS: The results demonstrated that WIN55 or SB treatment alone or together improved the pathological changes in mice with DSS colitis, decreased the plasma levels of TNF-alpha, and IL-6, and MPO activity in colon. SB 203580 48-50 tumor necrosis factor Mus musculus 170-179 26112872-8 2015 The observed effects of TNF-alpha on Na(+) currents were inhibited by pre-incubation with the NF-kappaB inhibitor BAY 11-7082 (1 muM) or the p38 mitogen-activated protein kinases (MAPK) inhibitor SB203580 (1 muM). SB 203580 196-204 tumor necrosis factor Mus musculus 24-33 22865777-7 2013 SB203580 also attenuated tactile allodynia/hyperalgesia or up-regulation of mTNF-alpha, but not the up-regulation of sTNF-alpha in the TNC. SB 203580 0-8 tumor necrosis factor Mus musculus 76-86 25371731-9 2014 By contrast, treatment with the p38 inhibitor, SB203580, decreased the levels of p-STAT3, TNF-alpha and IL-10 (P<0.05) following LPS stimulation. SB 203580 47-55 tumor necrosis factor Mus musculus 90-99 25371731-10 2014 SB203580 was shown to inhibit LPS-stimulated TNF-alpha expression (P<0.05) in a concentration-dependent manner, reaching significance at a concentration of 10 muM. SB 203580 0-8 tumor necrosis factor Mus musculus 45-54 24885161-9 2014 SB203580 significantly attenuated lung inflammation (neutrophil infiltration, mRNA expressions of TNF-alpha and MIP-2, protein levels of KC, MIP-1alpha, IL-1beta, and IL-6), proteinase expression (MMP-12 mRNA), oxidative DNA damage, and apoptosis caused by acute CS exposure. SB 203580 0-8 tumor necrosis factor Mus musculus 98-107 26648769-2 2015 Herein, we assessed whether the inhibition of p38 MAPK by SB203580 regulates LPS-induced expression of the inflammatory cytokines tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) in RAW264.7 and resident peritoneal macrophages. SB 203580 58-66 tumor necrosis factor Mus musculus 130-157 26648769-2 2015 Herein, we assessed whether the inhibition of p38 MAPK by SB203580 regulates LPS-induced expression of the inflammatory cytokines tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) in RAW264.7 and resident peritoneal macrophages. SB 203580 58-66 tumor necrosis factor Mus musculus 159-168 26648769-4 2015 The addition of SB203580 to cultures dramatically blocked LPS-induced TNF-alpha production in RAW264.7 and mouse resident peritoneal macrophages, and dramatically blocked LPS-induced IL-6 production in RAW264.7 macrophages, but not in mouse resident peritoneal macrophages. SB 203580 16-24 tumor necrosis factor Mus musculus 70-79 26648769-6 2015 However, LPS-stimulation significantly up-regulated the mRNA transcript levels of TNF-alpha and IL-6 in RAW264.7 and mouse resident peritoneal macrophages, whereas pretreatment with SB203580 dramatically down-regulated LPS-induced mRNA transcript levels of TNF-alpha and IL-6 in these cells. SB 203580 182-190 tumor necrosis factor Mus musculus 82-91 26648769-6 2015 However, LPS-stimulation significantly up-regulated the mRNA transcript levels of TNF-alpha and IL-6 in RAW264.7 and mouse resident peritoneal macrophages, whereas pretreatment with SB203580 dramatically down-regulated LPS-induced mRNA transcript levels of TNF-alpha and IL-6 in these cells. SB 203580 182-190 tumor necrosis factor Mus musculus 257-266 25563207-0 2015 Additive Suppression of LPS-Induced IL-10 and TNF-alpha by Pre-treatment of Dexamethasone and SB203580 in a Murine Alveolar Macrophage Cell Line (MH-S). SB 203580 94-102 tumor necrosis factor Mus musculus 46-55 25563207-5 2015 Pre-treatment of DEX or SB203580 inhibited lipopolysaccharide (LPS)-stimulated IL-10, TNF-alpha secretion, and STAT3 phosphorylation. SB 203580 24-32 tumor necrosis factor Mus musculus 86-95 24523867-8 2014 When we examined the anti-inflammatory effect of a p38 MAPK-specific inhibitor, SB203580, on microglial activation, we observed an identical inhibitory pattern as that of 4d and 4e, not only on NO and TNF-alpha production but also on the DNA binding activities of NF-kappaB and AP-1. SB 203580 80-88 tumor necrosis factor Mus musculus 201-210 23928505-4 2013 Exposure of LPS-stimulated neutrophils to sauchinone or SB203580, a p38 inhibitor, diminished production of tumor necrosis factor (TNF)-alpha and macrophage inflammatory protein (MIP)-2 compared to neutrophils cultured with LPS. SB 203580 56-64 tumor necrosis factor Mus musculus 108-141 23672639-12 2013 Intrathecal administration of SB203580, a p38 kinase inhibitor, significantly reduced mechanical allodynia, TNF-alpha expression in the subepidermal plexus, and increased both ELC and SLC populations during the period of mechanical allodynia. SB 203580 30-38 tumor necrosis factor Mus musculus 108-117 23898520-11 2013 RESULTS: (1) The DAI scores, the levels of TNF-alpha and IL-1beta in SB203580 group were lower significantly compared with DSS group (P < 0.05), and were increased significantly compared with normal control group (P < 0.05). SB 203580 69-77 tumor necrosis factor Mus musculus 43-52 23898520-12 2013 (2) The levels of TNF-alpha and IL-1beta in intestinal mucosal biopsy specimens in SB203580 treatment group were lower significantly than those in UC group (P < 0.05). SB 203580 83-91 tumor necrosis factor Mus musculus 18-27 23898520-13 2013 CONCLUSION: SB203580 can inhibit p38MAPK signal transduction pathway, then reduce the expression of pro-inflammatory cytokine TNF-alpha and IL-1beta. SB 203580 12-20 tumor necrosis factor Mus musculus 126-135 22763772-5 2012 SB203580 had less effect on MMP-9 and TNF-alpha expression under wear-debris-induced conditions. SB 203580 0-8 tumor necrosis factor Mus musculus 38-47 23690655-7 2013 Indeed, inhibition of p38 by SB203580 showed similar inhibitory activity of the production of TNF- alpha and PGE2 and the expression of TNF- alpha and COX-2 mRNA. SB 203580 29-37 tumor necrosis factor Mus musculus 94-104 23690655-7 2013 Indeed, inhibition of p38 by SB203580 showed similar inhibitory activity of the production of TNF- alpha and PGE2 and the expression of TNF- alpha and COX-2 mRNA. SB 203580 29-37 tumor necrosis factor Mus musculus 136-146 22763772-9 2012 SB203580 may notably inhibit wear-debris-induced inflammatory osteolysis by down-regulating expression of MMP-9 and TNF-alpha via the p38 MAPK pathway. SB 203580 0-8 tumor necrosis factor Mus musculus 116-125 22982779-10 2012 Anisomycin induced the production of TNF-alpha, which was abrogated in Nox2(-/-) mice and by treatment with SB203580, but not by disruption of p55/p75. SB 203580 108-116 tumor necrosis factor Mus musculus 37-46 21806874-4 2011 Pretreatment of PD98059 or U0126 inhibited TNF-induced IL-6 release and ERK phosphorylation in P815 cells (P<0.05), whereas pretreatment of SB203580 or AG490 hardly affect IL-6 release, with little effect on phosphorylation of p38 and STAT3 respectively. SB 203580 143-151 tumor necrosis factor Mus musculus 43-46 21590324-5 2012 Furthermore, JNK inhibitor SP600125, ERK inhibitor U0126, and p38 inhibitor SB203580 could all partially counteract NE"s effect on the phosphorylation of MAPKs, as well as TNF-alpha production by macrophages. SB 203580 76-84 tumor necrosis factor Mus musculus 172-181 22583683-12 2012 The addition of the p38 inhibitor SB203580 attenuated TNF-alpha production in both wild and autophagy-deficient Kupffer cells. SB 203580 34-42 tumor necrosis factor Mus musculus 54-63 17696256-6 2007 The effects of SB203580, a specific p38 MAPK inhibitor, on liver injuries and expression of proinflammatory cytokines (interferon-gamma, IL-12, IL-1beta and TNF-alpha) were observed. SB 203580 15-23 tumor necrosis factor Mus musculus 157-166 20606319-5 2010 A p38 inhibitor, SB203580, also inhibited the TNFalpha production dose-dependently. SB 203580 17-25 tumor necrosis factor Mus musculus 46-54 18095305-7 2008 PY plus LPS treatment elevated TNF-alpha production, and this was blocked by SP600125 or SB203580. SB 203580 89-97 tumor necrosis factor Mus musculus 31-40 18095305-13 2008 Liver mitochondria from PY plus LPS or PY plus TNF-alpha treated mice underwent calcium-dependent, cyclosporine A-sensitive swelling, which was prevented by SB203580 or SP600125. SB 203580 157-165 tumor necrosis factor Mus musculus 47-56 20956267-11 2010 IL-1beta, TNF-alpha, MMP-2 and MMP-9 mRNA levels were decreased in peritoneal cells of the SB203580 versus EM group (P < 0.01, P < 0.05, P < 0.05 and P < 0.05, respectively). SB 203580 91-99 tumor necrosis factor Mus musculus 10-19 20956267-12 2010 Concentrations of IL-1beta, TNF-alpha, MMP-2 and MMP-9 proteins in PF were reduced in the SB203580 versus EM group (P < 0.05, P < 0.01, P < 0.05 and P < 0.05, respectively). SB 203580 90-98 tumor necrosis factor Mus musculus 28-37 20482876-10 2010 Intrathecal delivery of SB203580, a p38 inhibitor, significantly inhibited the development of mechanical allodynia and the upregulation of COX2, iNOS and TNF-alpha. SB 203580 24-32 tumor necrosis factor Mus musculus 154-163 19954621-9 2009 (4) SB203580 and SP600125 down-regulated allogeneic T lymphocytes-induced VCAM-1, TNF-alpha, IFN-gamma, IL-6 expression in HUVECs. SB 203580 4-12 tumor necrosis factor Mus musculus 82-91 18255061-3 2008 Here we report that SB203580, a specific p38 MAPK inhibitor, which completely abolished LPS-induced TNF-alpha expression by the mouse macrophage cell RAW264.7 in normoxic conditions, lost the inhibitory effect in hypoxic conditions. SB 203580 20-28 tumor necrosis factor Mus musculus 100-109 16875982-9 2006 Under conditions of constant coronary flow, the p38-MAPK activation and contractile depression induced by TNFalpha, though attenuated, remained sensitive to the absence of MKK3 or the presence of SB203580. SB 203580 196-204 tumor necrosis factor Mus musculus 106-114 16954198-7 2006 Furthermore, using a kinase array, p38alpha was found to mediate LITAF phosphorylation and the inhibition of p38alpha with a p38-specific inhibitor (SB203580) blocked LITAF nuclear translocation and reduced LPS-induced TNF-alpha protein levels. SB 203580 149-157 tumor necrosis factor Mus musculus 219-228 16888021-6 2006 LPS-induced phospho-p38 MAPK levels were augmented by ethanol treatment and the p38 inhibitor, SB203580, prevented both the ethanol-induced increase in IL-10 production and the inhibitory effect of ethanol on TNF-alpha production. SB 203580 95-103 tumor necrosis factor Mus musculus 209-218 16875982-8 2006 The actions of TNFalpha were similarly attenuated in MAPK-activated protein kinase 2 (MK2)-deficient hearts, which have a marked reduction in myocardial p38-MAPK protein content, and by the p38-MAPK catalytic site inhibitor SB203580 (1 micromol/l). SB 203580 224-232 tumor necrosis factor Mus musculus 15-23 16875982-10 2006 The role of p38-MAPK in TNFalpha-induced contractile depression was confirmed in isolated murine cardiac myocytes exposed to SB203580 or lacking MKK3. SB 203580 125-133 tumor necrosis factor Mus musculus 24-32 14592977-6 2003 The activation of TAK1 by TNF-alpha, IL-1 or osmotic shock was also enhanced in embryonic fibroblasts from SAPK2a/p38alpha-deficient mice, while incubation of these cells with SB 203580 had no effect. SB 203580 176-185 tumor necrosis factor Mus musculus 26-35 16385569-3 2006 Treatment with a specific inhibitor, SP600125 or SB203580, in vitro suppressed TNF-alpha-induced migration and pulmonary metastasis. SB 203580 49-57 tumor necrosis factor Mus musculus 79-88 16438946-5 2005 Specific inhibitors for the signal proteins, Rp cAMPS, H89, PD98059, and U0126, or SB203580, suppressed the signaling pathway and TNF-alpha expression. SB 203580 83-91 tumor necrosis factor Mus musculus 130-139 15351317-9 2004 Additionally, curcumin and SB203580 suppressed PG-induced production of nitric oxide (NO) and tumor necrosis factor-alpha (TNF-alpha), whereas PD98059 showed an inhibitory effect only on the TNF-alpha production. SB 203580 27-35 tumor necrosis factor Mus musculus 94-121 15351317-9 2004 Additionally, curcumin and SB203580 suppressed PG-induced production of nitric oxide (NO) and tumor necrosis factor-alpha (TNF-alpha), whereas PD98059 showed an inhibitory effect only on the TNF-alpha production. SB 203580 27-35 tumor necrosis factor Mus musculus 123-132 15331624-4 2004 Pharmacological suppression of p38 or ERK1/2 MAPK with specific inhibitors (SB203580, SB202190, U0126, or PD98059) significantly attenuated LPS-induced TNF production but failed to inhibit LPS-induced HMGB1 release. SB 203580 76-84 tumor necrosis factor Mus musculus 152-155 15034939-8 2004 SB203580 and PD169316, specific inhibitors of p38 MAP kinase, significantly reduced the enhancement by IL-17 of TNF-alpha-stimulated IL-6 synthesis. SB 203580 0-8 tumor necrosis factor Mus musculus 112-121 15034939-11 2004 SB203580 and PD169316 inhibited the amplification by anisomycin of the TNF-alpha-induced IL-6 synthesis. SB 203580 0-8 tumor necrosis factor Mus musculus 71-80 14980980-15 2004 The selective p38 MAPK inhibitor, SB203580, inhibited the promoter activities of iNOS and COX-2 rather than that of TNF-alpha. SB 203580 34-42 tumor necrosis factor Mus musculus 116-125 15857937-6 2005 Using the specific p38 inhibitor (SB203580), we confirmed that the increase in tumor necrosis factor alpha production by LPS-stimulated burn macrophages requires p38 activation. SB 203580 34-42 tumor necrosis factor Mus musculus 79-106 14644621-10 2003 DON-induced TNF-alpha mRNA stabilization was abrogated in the presence of SB 203580, whereas the stabilization by DON was not affected by PD 98059 or SP 600125. SB 203580 74-83 tumor necrosis factor Mus musculus 12-21 12960069-9 2003 The differentiation of BMM phi into osteoclasts in response to receptor activator of nuclear factor-kappa B ligand or TNF alpha was strongly inhibited by SB203580. SB 203580 154-162 tumor necrosis factor Mus musculus 118-127 12871593-7 2003 Interestingly, PD98059, an inhibitor of ERK, inhibited p40-induced expression of TNF-alpha through the inhibition of C/EBPbeta, but not that of NF-kappaB, whereas SB203580, an inhibitor of p38 MAPK, inhibited p40-induced expression of TNF-alpha through the inhibition of both NF-kappaB and C/EBPbeta. SB 203580 163-171 tumor necrosis factor Mus musculus 235-244 14632659-9 2003 SB203580, a specific inhibitor of p38 MAPK, partially or markedly inhibited the phenotypic changes of DCs induced by TNF-alpha or DNCB, respectively. SB 203580 0-8 tumor necrosis factor Mus musculus 117-126 12759453-7 2003 This angiogenesis by TNF-alpha and sVCAM-1 was almost completely blocked by coadministration of SB203580 and also by neutralizing Ab against alpha(4) integrin. SB 203580 96-104 tumor necrosis factor Mus musculus 21-30 12392277-7 2002 Furthermore, PD98059 and SB203580 had an additive effect on TNF-alpha production, but PD98059 did not augment the SB203580-induced inhibition of IL-10 production. SB 203580 25-33 tumor necrosis factor Mus musculus 60-69 12509925-5 2002 RT-PCR was used to detect the influence of the MEK/REK inhibitor PD98059, JNK inhibitor SP600125, and p38 inhibitor SB203580 on the expression of TNF-alpha gene induced by LPS. SB 203580 116-124 tumor necrosis factor Mus musculus 146-155 12392277-6 2002 Inhibition of p38 MAPK with SB203580 inhibited the production of TNF-alpha and IL-10 by LPS-stimulated KCs, whereas blockade of ERK1/2 with PD98059 could reduce TNF-alpha production, but did not affect IL-10 production. SB 203580 28-36 tumor necrosis factor Mus musculus 65-74 11749068-6 2002 Apoptosis of LEC induced by Jo2/TNF was partially reversed by SB203580, a p38 inhibitor, suggesting that p38 is involved in apoptosis of these cells. SB 203580 62-70 tumor necrosis factor Mus musculus 32-35 11551956-6 2001 Specific inhibition of p38 MAP kinase activation by SB203580 in Kupffer cells or by overexpression of dominant negative p38 MAP kinase in RAW264.7 cells blocked ethanol-mediated TNFalpha mRNA stabilization. SB 203580 52-60 tumor necrosis factor Mus musculus 178-186